Clinical Trials on Late Platelet Aggregation in Belgium

Total 81 results

R&D Cardiologie

Completed

WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) (WOEST)

Atrial Fibrillation | Stents | Anticoagulants | Platelet Aggregation Inhibitors

Netherlands, Belgium
University Hospital Inselspital, Berne
European Cardiovascular Research Center

Completed

GLOBAL LEADERS Adjudication Sub-Study (GLASSY)

Coronary Artery Disease | Platelet-aggregation Inhibitors

Bulgaria, Switzerland, Austria, Belgium, Germany, Italy, Netherlands, Poland, United Kingdom
Universitaire Ziekenhuizen KU Leuven

Unknown

New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study

Alzheimer Disease, Late Onset

Belgium
Universitaire Ziekenhuizen KU Leuven

Unknown

Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Platelet Function

Belgium
Jessa Hospital

Completed

Safety of a Powder-free Latex Allergy Protocol in the Operating Theatre: A Prospective, Observational Cohort Study

Latex Hypersensitivity | Latex Allergy

Belgium
University Hospital, Ghent

Completed

The Value of Progesterone for the Timing of the Embryo Transfer in IVF/ICSI: a Prospective Randomised Trial

Clinical Pregnancy Rate

Belgium
University Hospital, Antwerp
Universiteit Antwerpen

Recruiting

Development of Artefact Removal and Physical Activity Algorithm (ARTEPHYSICAL)

Exercise | Heart Rate | Fitness Tracker

Belgium
KU Leuven

Completed

The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.

Impact of Legislation on Cumulative Delivery Rate

Belgium
Universitaire Ziekenhuizen KU Leuven
Research Foundation Flanders

Completed

Use of CBCT-based Tooth Replica in Tooth Autotransplantation to Improve the Outcome of Tooth Replacement in Children

Increase Success Rate of Tooth Transplantation

Belgium
Université Catholique de Louvain
Erasme University Hospital

Unknown

Non-invasive Modulation of Autonomic Cardiac Nervous System (MSNA)

Heart Rate Variability | Autonomic Nervous System | Muscle Sympathetic Nerve Activity

Belgium
Centre for Reproductive Medicine, Belgium

Completed

Implantation Rate of Vitrified-warmed Collapsed Blastocysts

Implantation Rate of Vitrified Blastocysts

Belgium
Vrije Universiteit Brussel

Terminated

Pre-Implantation Genetic Screening in Women Under the Age of 36 Years With Single Embryo Transfer

Live Birth Delivery Rate

Belgium
Ziekenhuis Oost-Limburg

Not yet recruiting

Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome? (USP)

Arthroplasty Complications | Tensor Fasciae Latae Syndrome

Belgium
University Hospital, Ghent

Completed

Heart Rate Variability at the Emergency Department

Heart Rate Variability | Emergency Department

Belgium
University Hospital, Antwerp

Completed

Neuromonitoring During Rapid Ventricular Pacing in Patients Undergoing Cerebral Aneurysm Surgery

Cerebral Arterial Aneurysm | Ventricular Rate Response Pacing

Belgium
Cliniques universitaires Saint-Luc- Université...

Active, not recruiting

PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock (PLACCSEPS)

Covid19 | Septic Shock | Inflammatory Response | Disseminated Intravascular Coagulation | Platelet Signal Processing Defect | Neutrophil Extracellular Trap Formation

Belgium
Atrial Fibrillation Network
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für...

Terminated

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH)

Atrial High Rate Episodes

Austria, Belgium, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Ukraine, United Kingdom, Denmark
University Hospital, Ghent

Completed

Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Atypical Hemolytic Uraemic Syndrome

Belgium
Sanofi
Bristol-Myers Squibb

Completed

Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)

Blood Platelet Disorders | Congenital Heart Defects

United States, France, Canada, Germany, Italy, Belgium
Meyer Children's Hospital IRCCS

Active, not recruiting

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Cytopenia

Italy, United States, Belgium
Novartis Pharmaceuticals

Completed

A Rollover Study to Provide Continued Treatment With Eltrombopag

Thrombocytopaenia

Belgium, Greece, Netherlands, Romania, China, Korea, Republic of, Tunisia, France, Hong Kong, Ireland, Peru, Poland
GlaxoSmithKline

Completed

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Thrombocytopaenia

United States, Germany, Israel, Belgium, Finland, Ireland, Italy, Greece, India, Czech Republic, Hungary, Canada, Poland
Omeros Corporation

Completed

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Thrombotic Microangiopathies

United States, Belgium, Bulgaria, Hong Kong, Italy, Lithuania, Malaysia, New Zealand, Poland, Singapore, Taiwan, Thailand
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Willebrand International Non-interventional Global Surveillance

Von Willebrand Disease

Norway, Germany, Italy, Belgium, Czechia, Finland, Greece
Hemab ApS

Recruiting

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Glanzmann Thrombasthenia

United States, Belgium, France, Italy, Netherlands, United Kingdom
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, Italy, China, Taiwan, Spain, Belgium, Poland, Portugal, Canada, Korea, Republic of, Australia, Brazil, Chile, Austria, Germany, Hungary, France, Argentina, United Kingdom, Thailand
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, China, Spain, Argentina, Belgium, Israel, Mexico, Romania, Japan, Brazil, Russian Federation, Germany, Italy, Czechia, Canada, Australia, France
Alexion Pharmaceuticals, Inc.

Recruiting

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Thrombotic Microangiopathy

United States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, China, Sweden, Australia, Canada, Poland
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
Amgen

Completed

Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training

Immune Thrombocytopenic Purpura

Spain, Austria, Belgium, Greece, United Kingdom, France, Germany, Netherlands
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Amicus Therapeutics

Terminated

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

United States, Canada, Australia, Belgium
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Primary Immune Thrombocytopenia

Austria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
Alexion Pharmaceuticals, Inc.

Terminated

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Thrombotic Microangiopathy

United States, Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, Canada, Korea, Republic of, Netherlands
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Alexion

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Atypical Hemolytic-Uremic Syndrome

United Kingdom, United States, France, Italy, Germany, Spain, Belgium
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Novo Nordisk A/S

Completed

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Congenital Bleeding Disorder | Glanzmann's Disease

Spain, Bulgaria, Pakistan, Belgium, Germany, France, United Kingdom, Italy, Hungary, Netherlands, United States, Algeria, Austria, Sweden, Switzerland
Momenta Pharmaceuticals, Inc.

Terminated

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Immune Thrombocytopenic Purpura (ITP)

United States, Poland, Hungary, Netherlands, Italy, Spain, Belgium
Genzyme, a Sanofi Company

Recruiting

Pompe Pregnancy Sub-Registry

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase Deficiency

Croatia, United States, Italy, Belgium, Czechia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Sanofi

Completed

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease

United States, Belgium, Spain, Italy, Turkey, Germany, Austria, France, Czechia, Russian Federation, Ukraine, United Kingdom, Netherlands
Symphogen A/S
Swedish Orphan Biovitrum

Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

United States, Belgium, Germany, India, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Von Willebrand Disease

Netherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Ablynx, a Sanofi company

Completed

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (TITAN)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia

Clinical Trials on Late Platelet Aggregation in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations